| Recruitment status | No longer recruiting |
| Unique ID issued by UMIN | UMIN000001552 |
| Receipt No. | R000001875 |
| Official scientific title of the study | Health-related quality of life of postmenopausal women treated with Letrozole as adjuvant therapy for hormone receptor-positive early breast cancer (SBCCSG-15) |
| Date of disclosure of the study information | 2008/12/05 |
| Last modified on | 2017/11/30 (Ver. 5) |
| Basic information | ||
| Official scientific title of the study | Health-related quality of life of postmenopausal women treated with Letrozole as adjuvant therapy for hormone receptor-positive early breast cancer (SBCCSG-15) | |
| Title of the study (Brief title) | Health-related quality of life of postmenopausal women treated with Letrozole as adjuvant therapy for hormone receptor-positive early breast cancer (SBCCSG-15) | |
| Region |
|
|
| Condition | |||
| Condition | postmenopausal breast cancer | ||
| Classification by specialty |
|
||
| Classification by malignancy | Malignancy | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | Evaluate health related quality of life during treated with Letrozole as adjuvant therapy for hormone receptor-positive early breast cancer and analyze by the difference of baseline characteristics ( e.g age, comorbidity, treatment ). Assess arthralgia, one of the most common adverse events, in detail. |
| Basic objectives2 | Others |
| Basic objectives -Others | HRQOL |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Change rate of FACT-ES score |
| Key secondary outcomes | Change rate of FACT-G score
Arthralgia related with AI FACT-ES score by baseline characters before and after treatment Difference of the evaluation of arthralgia between investigators and patients-self |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Letrozole 2.5mg daily p.o. as adjuvant therapy | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | 1. histologically diagnosed with unilateral primary breast cancer, stage 0-IIIC. ( previous local radiotherapy and/or systemic chemotherapy are allowed )
2. ER and/or PgR positive 3. PS(ECOG)0,1 4. postmenopausal patients who satisfies one or more below criteria; A. age 60 or more B. Prior bilateral oophorectomy C. amenorrheic for 1 year or more D. FSH and plasma estradiol level in postmenopausal ranges 5. adequate major organ function 6. informed consent has been obtained in writing |
|||
| Key exclusion criteria | 1. patients have been treated with medicine which may have some effect for sex hormone or trastuzumab
2. patients being treated with chemotherapy 3. Serious complications ( e.g malignant hypertension, CHF, hepatic failure, MI within 6 months, PE, arrhythmia treatment needed, infection, hemorrhagic tendency ) 4. active multiple cancer |
|||
| Target sample size | 200 | |||
| Research contact person | |
| Name of lead principal investigator | Toshio Tabei |
| Organization | Saitama Cancer Center |
| Division name | Breast Oncology |
| Address | 818 Komuro Ina Kitaadachi, Saitama 362-0806 |
| TEL | 048-722-1111 |
| toshikai@sbccsg.org | |
| Public contact | |
| Name of contact person | Toshihiro Kai |
| Organization | NPO Saitama Breast Cancer Clinical Study Group (SBCCSG) |
| Division name | Executive office(c/o: Shin-toshin Ladies MammoClinic) |
| Address | 3F, Capital Bldg. 4-261-1, Kishiki-cho, Omiya-ku, Saitama-City 330-0843, Saitama Prefecture |
| TEL | 048-600-1722 |
| Homepage URL | http://www.sbccsg.org/ |
| toshikai@sbccsg.org | |
| Sponsor | |
| Institute | NPO Saitama Breast Cancer Clinical Study Group (SBCCSG) |
| Institute | |
| Department | |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | No longer recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001875 |